Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
CLEOCIN HYDROCHLORIDE vs CLINDAMYCIN PALMITATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours.
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic